TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event

Risk & Weakness

Mike Webster: Overextended (Webby RSI)

25 Findings · last calculated September 18, 2026 Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Methodology & criteria

Mike Webster's caution/climax zone: the price has run ≥ 3 ATR (50-day) above the 21-EMA — measured with the Webby RSI 2.0. This far above the moving average, the move is overextended and often parabolic. Webster doesn't sell everything at the top but takes partial profits INTO strength and trails the stop to the low of the last few days. Not an entry signal but a profit-taking/risk signal.

Global filters: market cap of $50B or less (mega caps are cut from every scanner); 10- and 30-day ADR must be ≥ 1% (too little movement gets cut); fundamentally healthy names (Piotroski ≥ 5 or Fundamental Rating ≥ 55 out of 100) are excluded.

🔔 Watch scanner

Terms in This Scanner Explained

(17)
ADR (Average Daily Range)
The average daily swing of a stock in percent - measured over 10 or 30 trading days (columns "ADR 10D/30D"). An ADR of 5% means: on a normal day the gap between the intraday low and high runs about 5%. Traders look for movement - that is why stocks with an ADR under 1% are filtered out globally. Scanners that run without the global filters still include them; that is noted below their hit list. Not to be confused with ADR meaning "American Depositary Receipt" (a US certificate for foreign shares) - here ADR always means the daily swing.
AI Classification
Our company-by-company assessment of the AI boom based on SEC filings (the last four quarterly 10-Q reports and two annual 10-K reports): "Sells AI" (AI is a revenue source), "Threatened" (AI is a concrete business risk), "Uses AI" (operational use), or "Neutral" (no material AI exposure). Every classification requires at least two direct quote citations - otherwise the column shows "-". Not a quality judgment or a buy recommendation; the full file is on the stock page, methodology at /stocks/ai-rating-methodology.
Analysis (Full Company Analysis)
If the Analysis column shows "Read," there is an in-depth TickerGuard company analysis for this stock: business model, scanner findings, quarterly results, evidence from SEC filings, plus opportunities and risks. One click opens it directly.
ATR (Average True Range)
The average daily range in dollars (instead of percent like the ADR), including gaps. Often used as a yardstick: "3 ATR above the 21-EMA" means the price has run three normal daily moves above its trend line - significantly extended.
Avg/Yr 3Y (Average Annual Return)
The stock's average annual return over the past 3 years. Shows at a glance whether a stock delivers over the long run or just had a short hot streak.
Earnings Date
The date of the next quarterly earnings report. Price gaps in either direction are common around this date - that is why we color it red when it is 7 days away or less, and yellow when it is 14 days away or less: elevated risk for fresh positions.
EMA (Exponential Moving Average)
Like the simple moving average, but more recent prices carry more weight - the line follows price faster. The 21-day EMA is the standard short-term trend line for momentum traders.
EPS (Earnings per Share)
Quarterly earnings divided by the number of shares outstanding. The most important growth metric: if EPS rises strongly over several quarters, the company is earning more money per share.
Free Cash Flow (FCF)
Operating cash flow minus capital expenditures - the money left over for everything else (debt paydown, acquisitions, or buybacks). Consistently positive free cash flow is one of the most honest signs of a healthy business model.
Funda Rating (Fundamental Rating A+ to F)
Our proprietary fundamental rating from 0 to 100 points with a school-grade rank from A+ to F. 50 points is the average across the universe, 100 the best possible score. Every stock is scored against all others by percentile: growth in earnings and revenue, earnings surprises, analyst estimates, and quality criteria such as margins, cash flow, and balance-sheet strength. Grades: A+ from 95, A from 75, B from 55, C from 45, D from 25, E from 5, F below — A/A+ are the fundamentally strongest stocks in the universe.
Market Capitalization (Mkt Cap)
The market value of the company: share price x total shares outstanding, shown here in billions of dollars. Micro caps (< $0.3B) are small and volatile, mega caps (> $200B) are heavyweights. Our scanner universe is deliberately capped at $50B - we look for stocks with room to run. The cap does not apply to scanners that run without the global filters; that is noted below their hit list.
Net Margin
How much of revenue is left as profit? Net income divided by revenue, in percent. A 20% margin means: out of every dollar of revenue, 20 cents is left as profit. Rising margins are a strong quality signal.
Operating Cash Flow (OCF)
The cash that actually flows into the company from day-to-day operations - without accounting effects such as depreciation. A company can report book profits while still burning cash; operating cash flow reveals that.
Piotroski F-Score
A balance-sheet health check developed by Joseph Piotroski: 9 yes/no criteria covering earnings, cash flow, leverage, and efficiency produce a score from 0 to 9. Scores of 7 or higher are considered financially very solid, scores under 3 a warning sign.
Sector & Industry
Two levels of industry classification: sector is broad (e.g., Technology), industry is narrow (e.g., Semiconductors). Many strategies watch industry strength, because strong stocks are almost always found in strong industries.
Stage (Weinstein Stages 1-4)
Stan Weinstein divides every price chart into four stages: Stage 1 = basing (sideways after a downtrend), Stage 2 = uptrend (the only buying stage), Stage 3 = topping, Stage 4 = downtrend (avoid, or short candidate). Measured against the 30-week line (150-day moving average) and its slope.
Webby RSI
An indicator from Mike Webster (formerly of the O'Neil team): it measures how many ATRs the day's low sits above the 21-day EMA. Under 3 ATR = healthy trend; above that begins the overextended climax zone, where Webster takes partial profits instead of adding.

View all terms in the Scanner Glossary

Hit List

Filter

Rating (traffic light)

Stage

Funda Rating

Piotroski

Columns

This scanner's columns

Extra columns

Tip: clicking a column header sorts the table by that column; a second click flips the direction.

Mike Webster: Overextended (Webby RSI)
Symbol Earnings Avg/Y 3Y Volatility Stage Funda Rating Piotroski MktCap Industry AI Rating Deep Dive Deep-Dive Report Sector Price YTD 6 Mo. 1 Year Off High Price Target RS EPS Rating ADR 10D ADR 30D Beta P/E P/E (f) P/S P/B P/FCF PEG EV/EBITDA EBIT Margin Gross Margin Net Margin ROE ROA Debt/Eq Equity Ratio Sales +/Y Growth Score Div. Yield Payout Ratio Altman Z Inst. % Short % Analysts
SYRE Spyre Therapeutics Inc. 08/04 +290 % 68 % Stage 2 D 44 2 of 9 8.3 $ Biotechnology – — — Healthcare 92.70 $ +196.2 % +172.8 % +515.8 % −13.1 % +29.5 % 99 1 7.6 % 6.7 % 3.00 — 0.0 — 15.6 — — -8.0 0.0 % — 0.0 % -31.1 % -19.8 % — 87.8 % -100.0 % 2 0.0 % 0.0 % 9.5 93.2 % 14.4 % 4.8 (11)
ORKA Oruka Therapeutics, Inc. 08/10 +78 % 73 % Stage 2 D 37 1 of 9 6.0 $ Biotechnology – — — Healthcare 97.70 $ +175.2 % +188.0 % +502.9 % −4.8 % +58.6 % 98 42 7.5 % 6.8 % -0.21 — 0.0 — 12.5 — — 0.0 0.0 % — 0.0 % -27.3 % -13.0 % 0.00 96.5 % +1,105.3 % 2 0.0 % 0.0 % 34.0 89.1 % 17.1 % 4.9 (8)
DFTX Definium Therapeutics, Inc. 07/30 +332 % 74 % Stage 2 D 26 1 of 9 5.1 $ Biotechnology Neutral
Read
— Healthcare 38.70 $ +170.2 % +246.6 % +304.2 % −4.7 % +67.4 % 98 50 14.0 % 8.8 % 2.24 — 0.0 — 19.3 — — 0.0 0.0 % — 0.0 % -94.7 % -20.6 % — 69.5 % — — 0.0 % 0.0 % 1.4 65.6 % 7.4 % —
MBX MBX Biosciences, Inc. 08/06 — ⚠ Wildest 10% 105 % Stage 2 D 34 3 of 9 2.9 $ Biotechnology Neutral
Read
— Healthcare 63.90 $ +47.1 % +67.7 % +542.8 % −4.1 % +38.3 % 97 42 8.5 % 7.7 % 0.04 — 0.0 — 7.0 — — 0.0 0.0 % — 0.0 % -25.7 % -22.1 % 0.00 96.7 % — 2 0.0 % 0.0 % 37.2 111.5 % 12.1 % 4.6 (5)
OTLK OUTLOOK THERAPEUTICS INC 08/13 -32 % ⚠ Wildest 10% 164 % Stage 3 D 33 4 of 9 0.1 $ Biotechnology Uses AI
Read
— Healthcare 0.681 $ +7.6 % -7.7 % -33.2 % −52.5 % +642.4 % 97 42 16.8 % 20.7 % 0.75 — 2.8 — — — — -4.1 — -360.8 % 0.0 % -3.7 % -143.2 % — — +730.9 % 3 0.0 % 0.0 % -116.1 6.9 % 14.4 % 4.5 (6)
APGE Apogee Therapeutics, Inc. 08/10 — 63 % Stage 2 D 37 4 of 9 10.1 $ Biotechnology – — — Healthcare 135.10 $ +76.0 % +69.8 % +254.0 % −0.4 % -0.4 % 96 42 6.7 % 6.5 % 0.33 — 0.0 — 8.1 — — 0.0 0.0 % — 0.0 % -28.5 % -20.3 % 0.01 97.1 % — 3 0.0 % 0.0 % 40.3 131.6 % 7.3 % 5.0 (9)
BOLD Boundless Bio, Inc. 08/04 — 79 % Stage 2 E 24 1 of 9 0.1 $ Biotechnology – — — Healthcare 2.80 $ +116.7 % +9.0 % +145.6 % −10.0 % +42.9 % 95 42 4.8 % 4.4 % 0.44 — 0.0 — 0.7 — — 0.0 — — 0.0 % -50.2 % -32.8 % 0.56 — — 4 0.0 % 0.0 % -0.1 49.7 % 5.9 % 3.3 (3)
NVCT Nuvectis Pharma Inc 08/04 +1 % 84 % Stage 2 D 29 1 of 9 0.7 $ Biotechnology – — — Healthcare 21.40 $ +132.5 % +270.0 % +245.4 % −0.2 % +51.3 % 95 42 16.4 % 9.8 % -0.26 — 0.0 — — — — -7.4 — — 0.0 % -154.4 % -73.1 % — — -100.0 % 3 0.0 % 0.0 % -7.1 18.2 % 10.1 % 4.3 (6)
RFL Rafael Holdings, Inc. — +9 % 75 % Stage 2 D 33 2 of 9 0.1 $ Real Estate Services Neutral — — Real Estate 2.10 $ +126.3 % +167.8 % +46.1 % −8.1 % — 94 42 12.5 % 10.6 % 0.40 — 0.0 124.4 1.4 — — 5.4 — 95.1 % 0.0 % -37.6 % -22.8 % 0.01 — +44.0 % 3 0.0 % 0.0 % 0.8 7.3 % 3.7 % —
REPL Replimune Group Inc 07/02 -31 % ⚠ Wildest 10% 194 % Stage 3 D 43 1 of 9 1.1 $ Biotechnology Neutral
Read
— Healthcare 12.90 $ +17.5 % -40.2 % +125.4 % −15.9 % +51.2 % 92 42 9.2 % 10.0 % 0.94 — 0.0 — 5.4 — — -0.2 — — 0.0 % -90.9 % -51.3 % 0.36 — — 2 0.0 % 0.0 % -8.4 96.9 % 40.8 % 4.4 (8)
LPRO Open Lending Corp 08/05 -23 % 77 % Stage 2 D 38 3 of 9 0.4 $ Credit Services – — — Financial Services 3.10 $ +101.3 % +92.6 % +39.6 % −0.3 % -5.8 % 92 13 6.3 % 8.0 % 2.20 — 39.2 4.1 — — — 74.5 — 77.2 % -5.9 % -6.9 % 1.1 % — — +288.0 % 5 0.0 % 0.0 % 3.9 72.9 % 2.0 % 3.8 (8)
ALKS Alkermes Plc 08/04 +15 % 40 % Stage 2 C 53 1 of 9 7.8 $ Drug Manufacturers - Specialty & Generic – — — Healthcare 46.70 $ +71.8 % +84.2 % +67.6 % −1.6 % +19.9 % 90 9 4.8 % 4.2 % 0.26 54.4 133.3 4.7 4.7 35.1 1.96 39.6 -0.2 % 87.2 % 4.0 % 9.4 % 4.2 % 0.90 41.1 % -5.3 % 5 0.0 % 0.0 % 4.9 110.5 % 12.2 % 4.1 (15)
CLPT Clearpoint Neuro Inc 08/11 +61 % ⚠ Wildest 10% 100 % Stage 3 D 38 4 of 9 0.4 $ Medical Devices Neutral — — Healthcare 13.70 $ +35.5 % +34.1 % +28.9 % −40.3 % +78.0 % 90 42 11.6 % 9.0 % 1.27 — 12.1 9.8 22.5 — 0.61 -7.1 — 62.6 % -81.8 % -149.7 % -24.4 % 3.38 — +17.8 % 3 0.0 % 0.0 % -3.1 50.6 % 14.2 % 5.0 (2)
FDMT 4D Molecular Therapeutics Inc 08/10 -22 % 80 % Stage 3 C 49 4 of 9 0.8 $ Biotechnology – — — Healthcare 14.70 $ +54.7 % +59.0 % +120.4 % −6.7 % +107.2 % 89 50 10.5 % 8.5 % 2.73 — 0.0 8.4 2.0 — — -3.6 — -157.7 % -194.7 % -34.9 % -25.1 % 0.05 — +230,194.6 % 6 0.0 % 0.0 % 8.4 98.4 % 25.1 % 4.0 (12)
KYMR Kymera Therapeutics Inc 08/10 +109 % 59 % Stage 2 C 51 4 of 9 9.9 $ Biotechnology – — — Healthcare 118.50 $ +26.3 % +31.5 % +146.2 % −10.5 % +16.2 % 87 42 8.9 % 6.0 % 1.97 — 0.0 93.9 5.7 — — -9.5 -244.9 % -257.7 % -285.3 % -27.1 % -15.6 % 0.05 92.3 % -16.7 % 3 0.0 % 0.0 % 14.7 117.6 % 16.1 % 4.6 (20)
MNPR Monopar Therapeutics Inc 08/11 -10 % 68 % Stage 3 D 31 4 of 9 0.6 $ Biotechnology Neutral
Read
— Healthcare 102.70 $ +25.2 % +33.6 % +54.1 % −16.5 % +16.6 % 87 42 8.6 % 7.6 % 1.50 — 0.0 — 5.1 — — -2.4 — — 0.0 % -15.9 % -14.6 % 0.00 — -100.0 % 4 0.0 % 0.0 % 62.2 93.3 % 18.6 % 4.2 (5)
DNLI Denali Therapeutics Inc 08/10 -5 % 56 % Stage 2 D 40 2 of 9 3.2 $ Biotechnology – — — Healthcare 20.10 $ +50.0 % +52.4 % +54.1 % −4.8 % +79.4 % 85 42 5.3 % 5.3 % 1.01 — 0.0 886.1 3.4 — — 86.5 0.0 % -11,021.3 % 0.0 % -49.6 % -29.2 % 0.04 73.2 % -100.0 % 3 0.0 % 0.0 % 2.5 99.8 % 11.0 % 4.8 (19)
BHVN Biohaven Ltd. 08/10 -12 % ⚠ Wildest 10% 97 % Stage 3 C 45 2 of 9 2.2 $ Biotechnology – — — Healthcare 13.90 $ +30.9 % +38.3 % -5.5 % −17.4 % +53.0 % 78 42 9.3 % 8.9 % 3.17 — 0.0 — 17.6 — — -2.2 0.0 % — 0.0 % -333.0 % -72.0 % 2.21 27.8 % -100.0 % — 0.0 % 0.0 % -16.5 97.6 % 16.1 % 4.6 (16)
WNC Wabash National Corporation 07/24 -16 % 56 % Stage 2 D 39 2 of 9 0.5 $ Farm & Heavy Construction Machinery – — — Industrials 12.10 $ +48.3 % +56.9 % +13.8 % −0.6 % +80.0 % 78 97 9.6 % 6.9 % 1.43 — 8.6 0.3 1.5 — 0.73 2.0 — 1.0 % -5.5 % -17.8 % -3.2 % 1.66 — -20.8 % 5 2.6 % 6.3 % 4.6 100.8 % 10.5 % 4.0 (2)
GOLF Acushnet Holdings Corp 08/06 +41 % 30 % Stage 2 C 50 3 of 9 4.7 $ Leisure – — — Consumer Cyclical 81.60 $ +36.1 % +42.7 % +11.6 % 0 % +25.0 % 76 24 3.6 % 3.3 % 0.80 29.2 20.1 1.7 5.9 25.7 3.61 14.3 17.5 % 47.5 % 8.1 % 21.0 % 8.3 % 1.40 31.7 % +4.1 % 5 1.2 % 24.9 % 7.0 57.5 % 14.4 % 3.1 (8)
EPC Edgewell Personal Care Co 08/04 -11 % 42 % Stage 2 D 36 4 of 9 1.2 $ Household & Personal Products – — — Consumer Defensive 27.30 $ +56.0 % +61.6 % +34.6 % −6.4 % +17.8 % 76 18 7.1 % 5.8 % 0.40 — 13.0 0.6 — 18.3 2.87 18.1 9.3 % 40.9 % -4.2 % -0.7 % 3.0 % — 41.0 % -1.3 % 4 2.2 % 32.6 % 5.9 122.0 % 9.8 % 3.8 (9)
AQST Aquestive Therapeutics Inc 08/10 +58 % 82 % Stage 3 C 47 3 of 9 0.6 $ Drug Manufacturers - Specialty & Generic – — — Healthcare 4.70 $ -22.1 % -30.3 % -3.5 % −40.9 % +90.5 % 59 42 6.5 % 5.1 % 1.47 — 0.0 11.0 15.5 — — -1.8 — 67.0 % -144.6 % 0.0 % -29.2 % -3.92 — -22.6 % 3 0.0 % 0.0 % -5.4 60.6 % 21.3 % 4.6 (9)
RARE Ultragenyx 08/04 -14 % ⚠ Wildest 10% 97 % Stage 3 C 47 0 of 9 1.4 $ Biotechnology – — — Healthcare 14.50 $ +25.0 % -11.3 % -49.5 % −31.0 % +86.2 % 48 42 5.5 % 5.2 % 0.32 — 0.0 2.0 — — — -6.5 -102.2 % -20.8 % -81.7 % -608.5 % -24.2 % — -18.2 % +20.1 % 3 0.0 % 0.0 % -9.9 104.2 % 18.0 % 4.6 (20)
RGNX Regenxbio Inc 08/06 -16 % ⚠ Wildest 10% 99 % Stage 4 D 38 1 of 9 0.4 $ Biotechnology – — — Healthcare 8.20 $ -30.9 % -18.2 % -9.0 % −36.8 % +200.3 % 46 42 13.1 % 9.4 % 0.93 — 0.0 2.4 — — 0.26 -3.4 — -45.0 % -112.6 % -196.4 % -21.2 % — — +104.5 % 4 0.0 % 0.0 % -10.9 84.7 % 12.0 % 4.4 (12)
BWIN The Baldwin Insurance Group, Inc. 07/30 -1 % 61 % Stage 3 D 42 3 of 9 3.1 $ Insurance Brokers – — — Financial Services 32.00 $ +1.5 % +4.4 % +1.5 % −46.3 % +0.7 % 26 50 10.1 % 7.0 % 1.04 — 11.4 1.8 2.8 52.5 — 80.3 -17.5 % 31.3 % -4.7 % -6.2 % -0.9 % 2.67 16.2 % +9.4 % 3 0.0 % 0.0 % 3.4 94.5 % 13.7 % 3.8 (8)

Price Chart

Quarterly Figures

No quarterly data available.

Frequently Asked Questions

Mike Webster's caution/climax zone: the price has run ≥ 3 ATR (50-day) above the 21-EMA — measured with the Webby RSI 2.0. This far above the moving average, the move is overextended and often parabolic. Webster doesn't sell everything at the top but takes partial profits INTO strength and trails the stop to the low of the last few days. Not an entry signal but a profit-taking/risk signal.

All scanners are recalculated daily across the entire stock universe — most recently on September 18, 2026. The data basis is fundamental data and SEC filings (10-K annual reports and 10-Q quarterly reports).

Currently, 25 stocks pass this scanner's criteria (as of September 18, 2026).

Global filters: market cap of $50B or less (mega caps are cut from every scanner); 10- and 30-day ADR must be ≥ 1% (too little movement gets cut); fundamentally healthy names (Piotroski ≥ 5 or Fundamental Rating ≥ 55 out of 100) are excluded.

This scanner deliberately hunts for red flags — a hit is a finding, not a recommendation: like a smoke detector that beeps so you look in time. A hit is also not a bankruptcy verdict; most companies save themselves (say, through a capital raise, which dilutes existing shareholders). Portfolio owners use the list as an early-warning system, bargain hunters as an anti-shopping list, experienced traders as a watch list — it is never a buy or short recommendation.

Related scanners

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?